Moffitt Initiates Groundbreaking Clinical Trial With Oncolytic Virus for Non-Small Cell Lung Cancer
May 01, 2024
May 01, 2024
TAMPA, Florida, May 1 (TNSres) -- Moffitt Cancer Center issued the following news release:
Moffitt Cancer Center has launched a pioneering clinical trial for patients with late-stage non-small cell lung cancer whose disease has progressed following initial frontline standard of care immunotherapy that includes an immune checkpoint inhibitor alone or combined with chemotherapy. The innovative trial uses a novel oncolytic virus, MEM-288, in combination with the immune checkpoint inhib . . .
Moffitt Cancer Center has launched a pioneering clinical trial for patients with late-stage non-small cell lung cancer whose disease has progressed following initial frontline standard of care immunotherapy that includes an immune checkpoint inhibitor alone or combined with chemotherapy. The innovative trial uses a novel oncolytic virus, MEM-288, in combination with the immune checkpoint inhib . . .